Takeda Is Focused on Innovation Through R&D, CEO Says

The CEO of Takeda Pharmaceutical discusses the integration with Shire, highlighting the progress made in leadership and strategy. He addresses the company's debt management strategy, aiming to maintain an investment-grade rating through cash flow and asset disposals. The focus is on divesting non-core assets to streamline operations. The CEO also emphasizes the importance of innovation and strategic focus in selected therapy areas to stay competitive in the pharmaceutical industry.

What was a key focus in the integration of Takeda and Shire?

• Increasing product lines

• Nominating top leaders

• Reducing the workforce

• Expanding into new markets

How does Takeda plan to manage its debt effectively?

• Through government subsidies

• By increasing product prices

• By acquiring more companies

• Through cash flow and asset disposals

What percentage of Takeda's business is considered non-core?

• 25%

• 75%

• 50%

• 10%

What is Takeda's strategy to remain competitive in the pharmaceutical industry?

• Increasing marketing efforts

• Focusing on four therapy areas

• Reducing research and development

• Expanding into unrelated industries

Which company was mentioned as having acquired Celgene?

• Novartis

• Johnson & Johnson

• Pfizer

• Bristol Myers Squibb